Cu

OTC products · Product label record

Curist Mucus Relief Maximum Strength drug information

GUAIFENESIN
Little Pharma, Inc. · ORAL

Product NDC: 72559-013

Join the community
CommunityExperiencesReviewsDrug database
Source label information, not individualized medical advice. This record applies to the product and labeler shown below. Compare the exact formulation, strength and country with your package and the current source label.
Generic nameGUAIFENESIN
Labeler / manufacturerLittle Pharma, Inc.
RouteORAL
Drug classExpectorant
Product NDC72559-013
Label effective date2026-08-24

Official product label reference

Curist Mucus Relief Maximum Strength — Little Pharma, Inc.

This page contains 14 source sections for GUAIFENESIN, oral route. Label set c7d1136c-a712-2ac5-e053-2995a90a4dd4, version 10.

Retrieved 2026-10-02 · openFDA dataset updated 2026-10-02 · Check the current DailyMed label

Label records can cover multiple strengths or package sizes. A label listing does not by itself establish FDA approval or current market availability. Check the source and application history for this specific product.

Uses described in the label

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

Purpose

Purpose Expectorant
Dosage and administration — label text
Directions do not crush, chew, or break tablet take with a full glass of water this product can be administered without regard for the timing of meals adults and children 12 years of age and over: 1 tablet every 12 hours. Do not exceed 2 tablets in 24 hours. children under 12 years of age: do not use
Warnings
Warnings Do not use for children under 12 years of age Ask a doctor before use if you have persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema cough accompanied by too much phlegm (mucus) Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache. These could be signs of a serious illness. If pregnant or breast-feeding, ask a health professional before use.
Unclassified section
Drug Facts Distributed by: Little Pharma, Inc. New York, NY 10023 Made in India
Active ingredient
Active ingredient (in each extended-release tablet) Guaifenesin 1200 mg
Do not use
Do not use for children under 12 years of age
Ask a doctor before use
Ask a doctor before use if you have persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema cough accompanied by too much phlegm (mucus)
When to stop use and seek help
Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache. These could be signs of a serious illness.
Pregnancy or breast feeding
If pregnant or breast-feeding, ask a health professional before use.
Child safety
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
Storage and handling
Other information Do Not Use if Printed Seal Under Cap Is Broken Or Missing store between 20°-25°C (68°-77°F)
Inactive ingredient
Inactive ingredients carbomer homopolymer type B, hypromellose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate
Questions
Questions? Contact 1-844-243-1241 or email hi@curistrelief.com

Official sources and product identifiers

Substances listed: GUAIFENESIN

RxNorm identifiers: 310621

Package NDC codes

72559-013-11, 72559-013-28, 72559-013-41, 72559-013-64, 72559-013-23

Further research and background

These are external searches for related information. Research, encyclopedia and news articles have not been imported into this product record.

Coverage and corrections

The text is extracted from a US structured product label. Tables are represented as text where supplied; formatting and illustrations may be lost. A missing section does not mean a risk is absent. This reference has not been independently reviewed by a clinician and is not a live safety-alert service.

Source retrieved 2026-10-02. Read the source policy.